Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

160 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Selection and evaluation of preoperative systemic inflammatory response biomarkers model prior to cytoreductive nephrectomy using a machine-learning approach.
Laukhtina E, Schuettfort VM, D'Andrea D, Pradere B, Quhal F, Mori K, Sari Motlagh R, Mostafaei H, Katayama S, Grossmann NC, Rajwa P, Karakiewicz PI, Schmidinger M, Fajkovic H, Enikeev D, Shariat SF. Laukhtina E, et al. Among authors: schmidinger m. World J Urol. 2022 Mar;40(3):747-754. doi: 10.1007/s00345-021-03844-w. Epub 2021 Oct 20. World J Urol. 2022. PMID: 34671856 Free PMC article. Clinical Trial.
Extended follow-up from JAVELIN Renal 101: subgroup analysis of avelumab plus axitinib versus sunitinib by the International Metastatic Renal Cell Carcinoma Database Consortium risk group in patients with advanced renal cell carcinoma.
Haanen JBAG, Larkin J, Choueiri TK, Albiges L, Rini BI, Atkins MB, Schmidinger M, Penkov K, Michelon E, Wang J, Mariani M, di Pietro A, Motzer RJ. Haanen JBAG, et al. Among authors: schmidinger m. ESMO Open. 2023 Jun;8(3):101210. doi: 10.1016/j.esmoop.2023.101210. Epub 2023 Apr 25. ESMO Open. 2023. PMID: 37104931 Free PMC article.
Sunitinib Rechallenge in Patients With Metastatic Renal Cell Carcinoma.
Nachbargauer S, Bruchbacher A, Fajkovic H, Remzi M, Schmidinger M. Nachbargauer S, et al. Among authors: schmidinger m. Clin Genitourin Cancer. 2020 Jun;18(3):e277-e283. doi: 10.1016/j.clgc.2019.11.006. Epub 2019 Dec 4. Clin Genitourin Cancer. 2020. PMID: 31902715 Clinical Trial.
PD1/PD-L1 therapy in metastatic renal cell carcinoma.
Bruchbacher A, Lemberger U, Hassler MR, Fajkovic H, Schmidinger M. Bruchbacher A, et al. Among authors: schmidinger m. Curr Opin Urol. 2020 Jul;30(4):534-541. doi: 10.1097/MOU.0000000000000788. Curr Opin Urol. 2020. PMID: 32453005 Review.
Systemic therapy for metastatic renal cell carcinoma in the first-line setting: a systematic review and network meta-analysis.
Mori K, Mostafaei H, Miura N, Karakiewicz PI, Luzzago S, Schmidinger M, Bruchbacher A, Pradere B, Egawa S, Shariat SF. Mori K, et al. Among authors: schmidinger m. Cancer Immunol Immunother. 2021 Feb;70(2):265-273. doi: 10.1007/s00262-020-02684-8. Epub 2020 Aug 5. Cancer Immunol Immunother. 2021. PMID: 32757054 Free PMC article.
The Predictive Value of Programmed Death Ligand 1 in Patients with Metastatic Renal Cell Carcinoma Treated with Immune-checkpoint Inhibitors: A Systematic Review and Meta-analysis.
Mori K, Abufaraj M, Mostafaei H, Quhal F, Fajkovic H, Remzi M, Karakiewicz PI, Egawa S, Schmidinger M, Shariat SF, Gust KM. Mori K, et al. Among authors: schmidinger m. Eur Urol. 2021 Jun;79(6):783-792. doi: 10.1016/j.eururo.2020.10.006. Epub 2020 Nov 7. Eur Urol. 2021. PMID: 33172722 Free article.
160 results